The evidence, up front.
Tesamorelin is one of the few peptides where the human evidence is unambiguous, randomized, and published in top-tier journals. Before the framing, here is the data.
Pooled findings across five RCTs
- −27.7 cm² mean VAT reduction (pooled meta-analysis of five RCTs)
- +1.42 kg lean body mass over 6 months — preserved through caloric flux
- ~5% lower hepatic fat versus placebo on imaging
- Improved triglycerides and CRP correlated with VAT reduction
- Increased adipose tissue density (Hounsfield Units) — the fat-quality signal — independent of fat-volume change
In a 2021 secondary analysis published in JCEM, tesamorelin improved the density of both visceral and subcutaneous adipose tissue independent of changes in fat volume. Patients whose VAT did not shrink still had healthier, less inflammatory, less ectopic-lipid-laden fat.
Primary references:
Falutz J, et al. NEJM 2007;357:2359–2370 (pivotal RCT).
Stanley TL, et al. JAMA 2014;312:380–389 (VAT and hepatic fat in HIV-associated lipodystrophy).
Stanley TL, et al. JCEM 2021 — fat-quality findings independent of fat-volume change.
Selected pooled meta-analyses cataloged in our evidence library.
Full physician summary of the 2026 pooled meta-analysis — including the emerging cognitive endpoint and how it shapes our prescribing. Tesamorelin — what the 2026 meta-analysis actually shows →
Now the framing — why this matters.
Patients on semaglutide and tirzepatide tell me a version of the same story by month four. The scale moves, the clothes fit, the labs look better — and then the scale stops moving. The waist measurement, especially in men, often lags the weight loss by another 8–12 weeks. Some never fully resolve.
This is the conversation I have most often in 2026, and it is the conversation tesamorelin was made for.
Why visceral fat is its own problem.
Visceral adipose tissue (VAT) — the fat surrounding the liver, pancreas, and intestines — behaves like an organ, not a storage depot. It secretes inflammatory cytokines, drives insulin resistance, and is the dominant signal behind metabolic syndrome. You can lose subcutaneous fat with caloric restriction or a GLP-1 and still carry metabolically active VAT.
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog. It triggers pulsatile, physiologic GH release, which in turn drives lipolysis preferentially in visceral depots. The effect is selective in a way that diet, GLP-1s, and most weight-loss tools are not.
Quality, not just quantity.
The fat-quality finding is what changes how I prescribe it. Two patients can lose the same scale weight on a GLP-1, but the patient on tesamorelin will have remodeled the metabolic character of the fat that remains. Triglycerides drop further. CRP drops further. ALT and AST drop further when hepatic steatosis is in the picture.
Put differently: tesamorelin doesn't only make there be less fat. It changes what kind of fat you have.
The clinical use case at Limitless.
Tesamorelin is not a first-line weight-loss tool, and it is not a substitute for a GLP-1. We use it in three specific scenarios:
1. The GLP-1 plateau patient.
Six months into semaglutide or tirzepatide, the scale has stopped moving but the waist measurement is still high, ALT is still elevated, or imaging shows persistent VAT. Adding tesamorelin (typically 1–2 mg subcutaneously nightly for 12–16 weeks) targets the depot the GLP-1 isn't reaching cleanly.
2. The "skinny visceral" patient.
Lean BMI, normal weight, central adiposity on DEXA or MRI, and metabolic labs that don't match the body habitus. These patients fall through the cracks of weight-loss medicine because the scale tells them everything is fine. Tesamorelin is mechanistically appropriate here.
3. The MASLD / NAFLD patient with mild-to-moderate hepatic steatosis.
The hepatic-fat reduction signal in tesamorelin trials is consistent enough that it earns a seat at the table for fatty-liver patients who are intolerant or under-responsive to GLP-1 therapy. We co-monitor LFTs and IGF-1 throughout.
What we monitor.
- IGF-1 at baseline, 6 weeks, and 12 weeks. Goal: keep within the upper-quartile of the age-adjusted reference range. Stop or dose-reduce if persistently above range.
- Fasting glucose & HbA1c at baseline and 12 weeks. GH-axis activation can transiently raise insulin resistance; in our experience, this is rare at 1–2 mg dosing.
- Waist circumference and DEXA visceral fat panel at baseline and 16 weeks.
- LFTs and lipid panel at baseline and 12 weeks — these are the metrics where the fat-quality signal shows up.
What this isn't.
Tesamorelin is not a cosmetic injectable, not a GH replacement, and not appropriate for everyone with belly fat. Active malignancy, uncontrolled diabetic retinopathy, pregnancy, and hypersensitivity are absolute contraindications. We screen carefully and we co-prescribe with a clear stop date — typically 16 weeks, then reassess.
The honest framing: tesamorelin is a precision tool with a narrow indication window and a strong mechanism. It rewards careful patient selection and disciplined monitoring. It punishes lazy prescribing.